Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New application of mangosteen to aspect of preparing medicines for treating focal segmental glomerulosclerosis

A glomerulosclerosis and foci segmental technology, which is applied in the field of medicine, can solve the problem that the therapeutic effect of α-mangosteen flavonoids has not been reported, and achieves the effect of high safety

Inactive Publication Date: 2017-03-29
刘国勇 +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the field of chronic kidney disease treatment, the therapeutic effect of α-mangosteen flavonoids has not been reported yet.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of mangosteen to aspect of preparing medicines for treating focal segmental glomerulosclerosis
  • New application of mangosteen to aspect of preparing medicines for treating focal segmental glomerulosclerosis
  • New application of mangosteen to aspect of preparing medicines for treating focal segmental glomerulosclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0030] The present invention will be further described below by specific examples. It should be understood that the embodiments of the present invention are used to illustrate the present invention rather than limit the present invention. The simple improvements made to the present invention according to the essence of the present invention all belong to the protection scope of the present invention.

[0031] The α-mangosteen flavone is extracted from the peel of the mangosteen, and the α-mangosteen flavone used in the present invention is purchased from Sigma Company of the United States.

[0032] The medicine comprises alpha-mangosteen flavone and a pharmaceutically acceptable carrier. Those skilled in the art can use α-mangosteen flavone directly or indirectly to prepare various pharmaceutically acceptable auxiliary materials required for different dosage forms, such as fillers, disintegrants, lubricants, binders, etc., with conventional methods Pharmaceutical preparation...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a mangosteen, in particular to new application of alpha-mangostin to an aspect of preparing medicines for treating focal segmental glomerulosclerosis. The alpha-mangostin extracted from mangosteen shells can obviously reduce the glomerulus and renal tubule fibrosis expression level, meanwhile, accelerates SIRT1 expression and inhibits NLRP3 expression, is obvious on effect of treating glomerulosclerosis, is higher in safety of clinical application, has no any side effects, and widens the path of treating the focal segmental glomerulosclerosis.

Description

technical field [0001] The invention relates to a new application of mangosteen, in particular to a new application of α-mangosteen flavone in the treatment of focal segmental glomerulosclerosis, and belongs to the field of medicine. Background technique [0002] Focal segmental glomerulosclerosis (FSGS) refers to partial (focal) glomeruli and / or glomerular capillary loops (segments) with focal segmental sclerosis or Hyaline degeneration, a type of glomerular disease without obvious cell proliferation, is one of the main causes of end-stage renal disease. The pathogenesis of primary FSGS is still unclear. Currently, it is believed that the occurrence, development and genetic background of the disease, circulating factors, podocyte injury and degeneration, hyperlipidemia, imbalance of mesangial matrix synthesis and degradation, and virus or toxin-mediated damage and other external factors are also important. The latest studies have confirmed that the inflammatory response a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/38A61K31/352A61K45/06A61P13/12
CPCA61K36/38A61K31/352A61K45/06
Inventor 刘国勇贺理宇
Owner 刘国勇
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com